Showing results (111-120 of 584) with videos related to

Sort By:
Pageof 59
Expert Opinion on Pharmacotherapy|February 17, 2021
An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an updateLuigi Cerbone, Jose Carlos Benitez, David Planchard, et al.
Critical Reviews in Oncology/Hematology|February 29, 2020
Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLCIosune Baraibar, Laura Mezquita, Ignacio Gil-Bazo, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|March 2, 2016
KRAS oncogene in lung cancer: focus on molecularly driven clinical trialsEmmanuelle Kempf, Benoît Rousseau, Benjamin Besse, et al.
Cancer Discovery|November 2, 2021
New Immunotherapy Combinations Enter the Battlefield of Malignant MesotheliomaMihaela Aldea, Jose Carlos Benitez, Nathalie Chaput, et al.
Therapeutic Advances in Respiratory Disease|November 6, 2019
Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experienceAngela Botticella, Laura Mezquita, Cecile Le Pechoux, et al.
Lung Cancer (Amsterdam, Netherlands)|December 23, 2021
Antibody-drug conjugates: A promising novel therapeutic approach in lung cancerAakash Desai, Pamela Abdayem, Alex A Adjei, et al.
The Lancet Regional Health. Europe|July 23, 2024
Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort studyAdrien Rousseau, Stefan Michiels, Noémie Simon-Tillaux, et al.
Clinical Lung Cancer|November 23, 2021
PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung TrialJérôme Doyen, Benjamin Besse, Matthieu Texier, et al.
Translational Lung Cancer Research|July 23, 2021
Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?Lizza E L Hendriks, Jordi Remon, Jessica Menis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2019
Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation?Diego Enrico, Angelo Paci, Nathalie Chaput, et al.
Pageof 59